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Abstract The rapid and continuing progress in gene dis-
coveryforcomplexdiseasesisfuelinginterestinthepotential
application of genetic risk models for clinical and public
healthpractice.Thenumberofstudiesassessingthepredictive
abilityissteadilyincreasing,butthequalityandcompleteness
of reporting varies. A multidisciplinary workshop sponsored
by the Human Genome Epidemiology Network developed a
checklist of 25 items recommended for strengthening the
reporting of Genetic RIsk Prediction Studies (GRIPS),
building on the principles established by prior reporting
guidelines. These recommendations aim to enhance the
transparency of study reporting, and thereby to improve the
synthesisandapplicationofinformationfrommultiplestudies
that might differ in design, conduct, or analysis. A detailed
Explanation and Elaboration document is published.
Keywords Genetic  Risk prediction  Methodology 
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Abbreviations
GRIPS Genetic risk prediction studies
HuGENet Human genome epidemiology network
REMARK Guidelines for reporting of tumor marker
studies
STARD Standards for reporting diagnostic accuracy
STREGA Strenghtening the reporting of genetic
association studies
STROBE Strengthening the reporting of observational
studies in epidemiology
Introduction
The recent successes of genome-wide association studies
and the promises of whole genome sequencing fuel interest
in the translation of this new wave of basic genetic
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DOI 10.1007/s10654-011-9552-yknowledge to health care practice. Knowledge about
genetic risk factors may be used to target diagnostic, pre-
ventive, and therapeutic interventions for complex disor-
ders based on a person’s genetic risk, or to complement
existing risk models based on classical nongenetic factors
such as the Framingham risk score for cardiovascular dis-
ease. Implementation of genetic risk prediction in health
care requires a series of studies that encompass all phases
of translational research [1, 2], starting with a compre-
hensive evaluation of genetic risk prediction.
With increasing numbers of discovered genetic markers
that can be used in future genetic risk prediction studies, it
is crucial to enhance the quality of the reporting of these
studies, since valid interpretation could be compromised
by the lack of reporting of key information. Information
that is often missing includes details in the description of
how the study was designed and conducted (e.g., how
genetic variants were selected and coded, how risk models
or genetic risk scores were constructed, and how risk
categories were chosen), or how the results should be
interpreted. An appropriate assessment of the study’s
strengths and weaknesses is not possible without this
information. There is ample evidence that prediction
research often suffers from poor design and bias, and
these may also have an impact on the results of the studies
and on models of disease outcomes based on these studies
[3–5]. Although most prognostic studies published to date
claim signiﬁcant results [6, 7], very few translate to
clinically useful applications. Just as for observational
epidemiological studies [8], poor reporting complicates
the use of the speciﬁc study for research, clinical, or
public health purposes and hampers the synthesis of evi-
dence across studies.
Reporting guidelines have been published for various
research designs [9], and these contain many items that are
also relevant to genetic risk prediction studies. In particu-
lar, the guidelines for genetic association studies (STRE-
GA) have relevant items on the assessment of genetic
variants, and the guidelines for observational studies
(STROBE) have relevant items about the reporting of study
design. The guidelines for diagnostic studies (STARD) and
those for tumor marker prognostic studies (REMARK)
include relevant items about test evaluation; the REMARK
guidelines also have relevant items about risk prediction
[10–13]. However, none of these guidelines are fully suited
to genetic risk prediction studies, an emerging ﬁeld of
investigation with speciﬁc methodological issues that need
to be addressed, such as the handling of large numbers of
genetic variants (from 10 s to 10,000 s) and ﬂexibility in
handling such large numbers in analyses. We organized a
2-day workshop with an international group of risk pre-
diction researchers, epidemiologists, geneticists, method-
ologists, statisticians, and journal editors to develop
recommendations for the reporting of Genetic RIsk
Prediction Studies (GRIPS).
Genetic risk prediction studies
Genetic risk prediction studies typically develop or validate
models that predict the risk of disease, but they are also
being investigated for use in predicting prognostic out-
come, treatment response, or treatment-related harms. Risk
prediction models are statistical algorithms, which may be
simple genetic risk scores (e.g., risk allele counts), may be
based on regression analyses (e.g., weighted risk scores or
predicted risks), or may be based on more complex analytic
approaches such as support vector machine learning or
classiﬁcation trees. The risk models may be based on
genetic variants only, or include both genetic and nonge-
netic risk factors [14].
Aims and use of the GRIPS statement
The 25 items of the GRIPS statement are intended to
maximize the transparency, quality, and completeness of
reporting on research methodology and ﬁndings in a par-
ticular study. It is important to emphasize that these rec-
ommendations are guidelines only for how to report
research and do not prescribe how to perform genetic risk
prediction studies. The guidelines do not support or oppose
the choice of any particular study design or method, e.g.,
the guidelines recommend that the study population should
be described, but do not specify which population is pre-
ferred in a particular study.
The intended audience for the reporting guidelines is
broad and includes epidemiologists, geneticists, statisti-
cians, clinician scientists, and laboratory-based investiga-
tors who undertake genetic risk prediction studies, as well
as journal editors and reviewers who have to appraise the
design, conduct and analysis of such studies. In addition, it
includes ‘‘users’’ of such studies who wish to understand
the basic premise, design, and limitations of genetic pre-
diction studies in order to interpret the results for their
potential application in health care. These guidelines are
also intended to ensure that essential data from future
genetic risk prediction studies are presented in standardized
form, which will facilitate information synthesis as part of
systematic reviews and meta-analyses.
Items presented in the checklist are relevant for a wide
array of risk prediction studies, because GRIPS focuses on
the main aspects of the design and analysis of risk pre-
diction studies. GRIPS does not address randomized trials
that may be performed to test risk models, nor does it
speciﬁcally address decision analyses, cost-effectiveness
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123analyses, assessment of health care needs, or assessment of
barriers to health care implementation [15]. Once the per-
formance of a risk model has been established, these next
steps toward implementation require further evaluation
[10, 16]. For the reporting of these studies, which go
beyond the assessment of genetic risk models as such,
additional requirements apply. However, proper docu-
mentation of genetic predictive research according to
Table 1 Reporting recommendations for evaluations of risk prediction models that include genetic variants
Title and abstract
1 (a) Identify the article as a study of risk prediction using genetic factors. (b) Use recommended keywords
in the abstract: genetic or genomic, risk, prediction
Introduction
Background and rationale 2 Explain the scientiﬁc background and rationale for the prediction study
Objectives 3 Specify the study objectives and state the speciﬁc model(s) that is/are investigated. State if the study concerns
the development of the model(s), a validation effort, or both
Methods
Study design and setting 4
a Specify the key elements of the study design and describe the setting, locations, and relevant dates, including
periods of recruitment, follow-up, and data collection
Participants 5
a Describe eligibility criteria for participants, and sources and methods of selection of participants
Variables: deﬁnition 6
a Clearly deﬁne all participant characteristics, risk factors and outcomes. Clearly deﬁne genetic variants using a
widely-used nomenclature system
Variables: assessment 7
a (a) Describe sources of data and details of methods of assessment (measurement) for each variable. (b) Give a
detailed description of genotyping and other laboratory methods
Variables: coding 8 (a) Describe how genetic variants were handled in the analyses. (b) Explain how other quantitative variables
were handled in the analyses. If applicable, describe which groupings were chosen, and why
Analysis: risk model
construction
9 Specify the procedure and data used for the derivation of the risk model. Specify which candidate variables
were initially examined or considered for inclusion in models. Include details of any variable selection
procedures and other model-building issues. Specify the horizon of risk prediction (e.g., 5-year risk)
Analysis: validation 10 Specify the procedure and data used for the validation of the risk model
Analysis: missing data 11 Specify how missing data were handled
Analysis: statistical
methods
12 Specify all measures used for the evaluation of the risk model including, but not limited to, measures
of model ﬁt and predictive ability
Analysis: other 13 Describe all subgroups, interactions, and exploratory analyses that were examined
Results
Participants 14
a Report the numbers of individuals at each stage of the study. Give reasons for nonparticipation at each stage.
Report the number of participants not genotyped, and reasons why they were not genotyped
Descriptives: population 15
a Report demographic and clinical characteristics of the study population, including risk factors used in the risk
modeling
Descriptives: model
estimates
16 Report unadjusted associations between the variables in the risk model(s) and the outcome. Report adjusted
estimates and their precision from the full risk model(s) for each variable
Risk distributions 17
a Report distributions of predicted risks and/or risk scores
Assessment 18 Report measures of model ﬁt and predictive ability, and any other performance measures, if pertinent
Validation 19 Report any validation of the risk model(s)
Other analyses 20 Present results of any subgroup, interaction, or exploratory analyses, whenever pertinent
Discussion
Limitations 21 Discuss limitations and assumptions of the study, particularly those concerning study design, selection of
participants, and measurements and analyses, and discuss their impact on the results of the study
Interpretation 22 Give an overall interpretation of results considering objectives, limitations, multiplicity of analyses, results
from similar studies, and other relevant evidence
Generalizability 23 Discuss the generalizability and, if pertinent, the health care relevance of the study results
Other
Supplementary
information
24 State whether databases for the analyzed data, risk models, and/or protocols are or will become publicly
available and if so, how they can be accessed
Funding 25 Give the source of funding and the role of the funders for the present study. State whether there are any
conﬂicts of interest
a Marked items should be reported for every population in the study
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into clinical and public health practice.
Development of the GRIPS statement
The GRIPS statement was developed by a multidisciplin-
ary panel of 25 risk prediction researchers, epidemiolo-
gists, geneticists, methodologists, statisticians, and journal
editors, seven of whom were also part of the STREGA
initiative [11]. They attended a 2-day meeting in Atlanta,
Georgia (US) in December 2009 that was sponsored by the
US Centers for Disease Control and Prevention on behalf
of the Human Genome Epidemiology Network (HuGENet)
[17]. Participants discussed a draft version of the guidelines
that was prepared and distributed before the meeting. This
draft version was developed on the basis of existing
reporting guidelines, namely STREGA [11], REMARK
[13], and STARD [12]. These were selected out of all
available guidelines (see http://www.equator-network.org)
because of their focus on observational study designs and
genetic factors (STREGA), prediction models (REMARK),
and test evaluation (REMARK and STARD). During the
meeting, methodological issues pertinent to risk prediction
studies were addressed in presentations. Workshop partic-
ipants were asked to change, combine, or delete proposed
items and add additional items if necessary. Participants
had extensive post-meeting electronic correspondence. To
harmonize our recommendations for genetic risk prediction
studies with previous guidelines, we chose the same
wording for the items wherever possible. Finally, we tried
to create consistency with previous guidelines for the
evaluation of risk prediction studies of cardiovascular
diseases and cancer [2, 18]. The ﬁnal version of the
checklist is presented in Table 1.
The GRIPS explanation and elaboration article
Accompanying this GRIPS statement, an Explanation and
Elaboration document has been written, modeled after those
developed for other reporting guidelines [19–22]. The
Explanation and Elaboration document illustrates each item
with at least one published example that we consider
transparent in reporting, explains the rationale for its
inclusion in the checklist, and presents details of the items
that need to be addressed to ensure transparent reporting.
The Explanation and Elaboration document was produced
after the meeting. The document was prepared by a small
subgroup and shared with all workshop participants for
additional revisions and ﬁnal approval.
Concluding remarks and future directions
High-quality reporting reveals the strengths and weaknesses
of empirical studies, facilitates the interpretation of the sci-
entiﬁc and health care relevance of the results—especially
within the framework of systematic reviews and meta-
analyses—and helps build a solid evidence base for moving
genomicdiscoveriesintoapplicationsinhealthcarepractice.
The GRIPS guidelines were developed to improve the
transparency, quality and completeness of the reporting of
genetic risk prediction studies. As outlined in the introduc-
tion, GRIPS does not prescribe how studies should be
designed, conducted, or analyzed, and therefore the guide-
lines should not be used to assess the quality of empirical
studies [23]. The guidelines should be used only to check
whether all essential items are adequately reported.
Finally, the methodology for designing and assessing
genetic risk prediction models is still developing. For
example, newer measures of reclassiﬁcation were ﬁrst
introduced in 2007 [24], and several alternative reclassiﬁ-
cation measures have been proposed [25]. Which measures
to apply and when to use measures of reclassiﬁcation are
still subject to ongoing evaluation and discussion [26].
Furthermore, alternative strategies for constructing risk
models other than simple regression analyses are being
explored, and these may add increased complexity to the
reporting. In formulating the items of the GRIPS statement,
these methodological advances were anticipated. It is for
this reason that the GRIPS statement recommends how a
study should be reported and not how a study should be
conducted or analyzed. Therefore, methodological and
analytical developments will not immediately impact the
validity and relevance of the items, but the GRIPS state-
ment will be updated when this is warranted by essential
new developments in the construction and evaluation of
genetic risk models.
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